Algeta ASA said it expects to make regulatory filings in the US and Europe by mid-2012 for its radiopharmaceutical, Alpharadin, following a Phase 3 trial which showed improved survival in patients with prostate cancer and bone metastases. ---Subscribe to MedNous to access this article--- Company News
